Indivior PLC (LON:INDV - Get Free Report) traded up 11.1% on Friday . The stock traded as high as GBX 799 ($10.72) and last traded at GBX 772 ($10.35). 551,238 shares were traded during mid-day trading, a decline of 49% from the average session volume of 1,087,031 shares. The stock had previously closed at GBX 695 ($9.32).
Indivior Stock Performance
The firm has a 50 day moving average of GBX 725.17 and a 200-day moving average of GBX 804.32. The company has a market cap of £1.34 billion, a P/E ratio of -711.82, a PEG ratio of -5.57 and a beta of 0.19. The company has a quick ratio of 1.52, a current ratio of 0.83 and a debt-to-equity ratio of -170.06.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
